课题基金 / 基金详情

Accelerated discovery of synthetic polymers for ribonucleoprotein delivery through the integration of active learning, machine learning, and polymer science

Accelerated discovery of synthetic polymers for ribonucleoprotein delivery through the integration of active learning, machine learning, and polymer science
通过整合主动学习、机器学习和聚合物科学,加速发现用于核糖核蛋白递送的合成聚合物
批准号:
10195432
负责人:
Connor Wilson Coley
金额:
$19.76万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-22 至 2023-08-31

项目摘要

项目成果

Connor Wilson Coley的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Gene editing systems such as CRISPR/Cas9 have rapidly grown in popularity as research tools and hold the potential to cure a diverse set of genetic disorders. However, effective, safe, and effective delivery remains a significant challenge for therapeutic translation and for application to cell types that are difficult to culture ex vivo. Ideally, intact Cas9 protein would be delivered with its guide RNA (sgRNA) as a purified ribonucleoprotein (RNP), as opposed to Cas9-encoding mRNA or plasmids, to minimize off-target effects. Viral vectors (e.g., AAVs) cannot deliver such large cargo due to their limited capsid size, which exhibit additional challenges with respect to immunogenicity, cost, and manufacturability. Fortunately, synthetic polymers--widely studied in the context of nucleic acid delivery and as biomaterials--have recently shown promise as vehicles for in vivo delivery of sgRNA- Cas9 RNPs. However, there are no consistent design principles by which novel synthetic polymers with improved delivery efficiency, tissue specificity, and safety can be developed. There are far too many polymer structures to test exhaustively or through ad hoc experimentation, so a systematic approach to polymer design, synthesis, and evaluation is required to identify promising candidates. This proposal presents a framework for the discovery of functional polymers through Bayesian experimental design. Machine learning models trained on experimental outcomes will serve as surrogates for experimentation in order to virtually screen a massive library of potential polymer candidates. Polymer candidates will be selected algorithmically through Bayesian Optimization to balance exploration of unknown chemical space and exploitation of structures known to effectively deliver RNPs. Aim 1 will involve (a) the synthesis of a diverse library of biodegradable poly(ester urea amines) (PEUAs), (b) the evaluation of their functional performance using a model fluorescent reporter knock-in/knock-out assay, a cell viability assay, and a metabolic activity assay, and (c) the development and validation of a machine learning model to learn a quantitative relationship between polymer structure/composition and these multiple performance metrics. Aim 2 will involve (a) the enumeration of the chemical space of synthetically accessible PEUAs, and (b) the development and application of a Bayesian Optimization framework leveraging the machine learning model from Aim 1 to guide the selection of candidate polymers from the enumerated space through iterative rounds of experimentation. The outcome of the proposed work will be an integrated tool combining machine learning and polymer science for the unbiased exploration of a broad biomaterial design space, validated through the development of effective and safe RNP delivery vehicles for gene editing that outperform existing commercial polymeric vehicle solutions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthesizability-constrained expansion and multi-objective evolution of antitubercular compounds
  • 批准号:
    10430402
  • 项目类别:
  • 资助金额:
    $19.73万
  • 财政年份:
    2022
  • 负责人:
    Connor Wilson Coley
  • 依托单位:
Informatics and Machine Learning Modules for Research Planning, Scheduling, Simulation, and Optimization in the ASPIRE Autonomous Laboratory
Informatics and Machine Learning Modules for Research Planning, Scheduling, Simulation, and Optimization in the ASPIRE Autonomous Laboratory
Synthesizability-constrained expansion and multi-objective evolution of antitubercular compounds
海外基金